Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acticor, Aridis, Ascentage, Cocrystal, IGM, Pepgen, Pharmazz, Precigen, Rocket.
Insilico Medicine IP Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Researchers from NYU Grossman School of Medicine reported on a new strategy intended to provide long-term protection against the SARS-CoV-2 virus using an experimental decoy.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akebia, Amylyx, Beigene, Bristol Myers Squibb, Inhibrx, Iovance, Janssen, Lexicon, Metriopharm, SK, Valneva.
Cansino Biologics Inc. reported positive data in a phase IIb trial evaluating the heterologous mRNA vaccine CS-2034 booster compared to an inactivated vaccine to prevent SARS-CoV-2 infections.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Biophytis, BMS, Curium, Gilead, Hutchmed, Inventiva, Ipsen, Novavax, Novo Nordisk, Sino, Takeda.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biophytis, Ferring, Genelux, Oxurion, Profoundbio, Structure, Theseus, TME, Xilio.
RSS
